Roles of PI3K/AKT/PTEN Pathway in the Pathogenesis of Parkinson’s Disease and the Neuropsychiatric Symptoms

References (55)

1. 1 PHARMACOLOGY AND FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTORS [DOI]
2. 2 PI3K/AKT/mTOR Pathway in Angiogenesis [DOI]
3. 3 The mitochondrial protease HtrA2 is regulated by Parkinson's disease-associated kinase PINK1 [DOI]
4. 4 Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling [DOI]
5. 5 Fucoidan induces apoptosis of human HS-Sultan cells accompanied by activation of caspase-3 and down-regulation of ERK Pathways [DOI]
6. 6 Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function [DOI]
7. 7 Targeting PI3 Kinase/AKT/mTOR Signaling in Cancer [DOI]
8. 8 AKT/GSK3 signaling pathway and schizophrenia [DOI]
9. 9 Activation of the Unfolded Protein Response Is an Early Event in Alzheimer’s and Parkinson’s Disease [DOI]
10. 10 Roles of PI3K/AKT/GSK3/mTOR Pathway in Cell Signaling of Mental Illnesses [DOI]
11. 11 Beyond cAMP: the regulation of Akt and GSK3 by dopamine receptors [DOI]
12. 12 Validating GSK3 as an in vivo target of lithium action [DOI]
13. 13 Guanosine protects human neuroblastoma SH-SY5Y cells against mitochondrial oxidative stress by inducing heme oxigenase-1 via PI3K/Akt/GSK-3β pathway [DOI]
14. 14 Targeting Group III Metabotropic Glutamate Receptors Produces Complex Behavioral Effects in Rodent Models of Parkinson's Disease [DOI]
15. 15 Molecular Insights into Parkinson's Disease [DOI]
16. 16 Guanosine produces an antidepressant-like effect through the modulation of NMDA receptors, nitric oxide–cGMP and PI3K/mTOR pathways [DOI]
17. 17 Oestrogen Receptors and Signalling Pathways: Implications for Neuroprotective Effects of Sex Steroids in Parkinson’s Disease [DOI]
18. 18 Targeting Glutamate Receptors to Tackle the Pathogenesis, Clinical Symptoms and Levodopa-Induced Dyskinesia Associated with Parkinson’s Disease [DOI]
19. 19 Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease [DOI]
20. 20 Native group‐III metabotropic glutamate receptors are coupled to the mitogen‐activated protein kinase/phosphatidylinositol‐3‐kinase pathways [DOI]
21. 21 Chronic But Not Acute Treatment with a Metabotropic Glutamate 5 Receptor Antagonist Reverses the Akinetic Deficits in a Rat Model of Parkinsonism [DOI]
22. 22 Kinases and kinase signaling pathways: Potential therapeutic targets in Parkinson's disease [DOI]
23. 23 Metabotropic Glutamate 5 Receptor Blockade Alleviates Akinesia by Normalizing Activity of Selective Basal-Ganglia Structures in Parkinsonian Rats [DOI]
24. 24 Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease [DOI]
25. 25 Metabotropic glutamate receptor 7: At the interface of cognition and emotion [DOI]
26. 26 Common factors among Alzheimer’s disease, Parkinson’s disease, and epilepsy: Possible role of the noradrenergic nervous system [DOI]
27. 27 Therapeutic Potential of Group III Metabotropic Glutamate Receptors [DOI]
28. 28 Additive neuroprotection of GABA A and GABA B receptor agonists in cerebral ischemic injury via PI-3K/Akt pathway inhibiting the ASK1-JNK cascade [DOI]
29. 29 Gene Therapy in Parkinsonʼs Disease [DOI]
30. 30 Endocannabinoid-Mediated Long-Term Depression of Afferent Excitatory Synapses in Hippocampal Pyramidal Cells and GABAergic Interneurons [DOI]
31. 31 Functional significance of glycogen synthase kinase-3 regulation by serotonin [DOI]
32. 32 PI3K/AKT/PTEN Signaling as a Molecular Target in Leukemia Angiogenesis [DOI]
33. 33 Molecular alterations in AKT1, AKT2 and AKT3 detected in breast and prostatic cancer by FISH [DOI]
34. 34 Restriction of trophic factors and nutrients induces PARKIN expression [DOI]
35. 35 Modulation of the development of human monocyte‐derived dendritic cells by lithium chloride [DOI]
36. 36 Roles of GSK3 in metabolic shift toward abnormal anabolism in cell senescence [DOI]
37. 37 Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats [DOI]
38. 38 Metabotropic glutamate receptor 4 (mGlu4)-positive allosteric modulators for the treatment of Parkinson's disease: historical perspective and review of the patent literature [DOI]
39. 39 Opposite regulation of metabotropic glutamate receptor 3 and metabotropic glutamate receptor 5 by inflammatory stimuli in cultured microglia and astrocytes [DOI]
40. 40 PI3K/Akt signaling pathway-induced heme oxygenase-1 upregulation mediates the adaptive cytoprotection of hydrogen peroxide preconditioning against oxidative injury in PC12 cells [DOI]
41. 41 Glycogen synthase kinase-3β regulates etoposide-induced apoptosis via Bcl-2 mediated caspase-3 activation in C3H10T1/2 cells [DOI]
42. 42 Therapeutic Potential of Targeting Metabotropic Glutamate Receptors for Parkinson’s Disease [DOI]
43. 43 Neurotransmitter CART as a New Therapeutic Candidate for Parkinson’s Disease [DOI]
44. 44 Regulation of Akt and Wnt signaling by the group II metabotropic glutamate receptor antagonist LY341495 and agonist LY379268 [DOI]
45. 45 Characterization of PDK2 Activity Against Protein Kinase B γ [DOI]
46. 46 The common inositol-reversible effect of mood stabilizers on neurons does not involve GSK3 inhibition, myo-inositol-1-phosphate synthase or the sodium-dependent myo-inositol transporters [DOI]
47. 47 Effects of PPARγ agonists on cell survival and focal adhesions in a Chinese thyroid carcinoma cell line [DOI]
48. 48 Dopamine D2 Receptor-Mediated AKT/PKB Signalling: Initiation by the D2S Receptor and Role in Quinpirole-Induced Behavioural Activation [DOI]
49. 49 Contribution of Metabotropic Glutamate Receptor mGluR4 to L‐2‐[3H]Amino‐4‐Phosphonobutyrate Binding in Mouse Brain [DOI]
50. 50 Constitutively active group I mGlu receptors and PKMzeta regulate synaptic transmission in developing perirhinal cortex [DOI]
51. 51 Akt/GSK3 Signaling in the Action of Psychotropic Drugs [DOI]
52. 52 Function of COX-2 and Prostaglandins in Neurological Disease [DOI]
53. 53 Role of the TSC1-TSC2 Complex in the Integration of Insulin and Glucose Signaling Involved in Pancreatic β-Cell Proliferation [DOI]
54. 54 HEDONIC TONE AND ITS MOOD AND COGNITIVE CORRELATES IN PARKINSON'S DISEASE [DOI]
55. 55 Metabotropic receptors as targets for drugs of potential use in the treatment of neuropathic pain.

Cited by 11

Showing 4 of 11 known citations — external sources report more than can currently be individually listed.

Related research

• Case of an Adult with Attention Deficit/Hyperactivity Disorder: The Course of Treatment for Improvement in Processing Speed — shares topic coverage
• The Prevalence of Irritable Bowel Syndrome (IBS) in a Private-University in Malaysia, and Its Associated Factors Including Stress, Depression and Anxiety — shares topic coverage
• Early Impact of Lockdown on Daily Activity Behaviors and Sleep Pattern in Small Indian Population — shares topic coverage
• Prevalence and Comorbidity of Depression and Anxiety among Medical Students in Babcock University, Ogun State, Nigeria — shares topic coverage
• Psychological Wellbeing of Healthcare Workers in Different Hospitals of Karachi (Pakistan) During COVID-19 Pandemic — shares topic coverage